JGC
EVOK

J. Goldman & Co’s Evoke Pharma EVOK Stock Holding History

J. Goldman & Co’s Portfolio EVOK Stock Details EVOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-174
Closed -$52K – 377
2018
Q1 		$52K Hold
174
– – ﹤0.01% 334
2017
Q4 		$57K Buy
+174
New +$72.1K ﹤0.01% 308

Other funds holding EVOK

SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

J. Goldman & Co's EVOK Position: Q2 2018 in Review

J. Goldman & Co sold out of Evoke Pharma (EVOK) in Q2 2018, closing a stake of 174 shares — an estimated $52K sold.

J. Goldman & Co first reported a position in EVOK in Q4 2017 and held it in 2 quarters. The position peaked at $57K in Q4 2017. 20 funds tracked by Wall St. Rank hold EVOK as of Q2 2018.

  • J. Goldman & Co reported no remaining Evoke Pharma position as of Q2 2018 after selling out during the quarter.
  • J. Goldman & Co sold 174 Evoke Pharma shares in Q2 2018, an estimated $52K.
  • J. Goldman & Co first reported a position in Evoke Pharma in Q4 2017 and held it in 2 quarters.
  • J. Goldman & Co's Evoke Pharma position peaked at $57K in Q4 2017.
  • 20 funds tracked by Wall St. Rank held Evoke Pharma as of Q2 2018.

Based on J. Goldman & Co's 13F filing for Q2 2018, filed 14 Aug 2018.